Clinical Trial Update: "Safety, Tolerability and Pharmacokinetics of MP-376 Administered for 14 Days to Stable Pediatric (CF) Patients" [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, tolerability, and pharmacokinetics of MP-376 administered for 14 days to stable pediatric patients with cystic fibrosis. The re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• MP-376

Snippet

Sponsor: Amgen | Conditions: Cystic Fibrosis | Phase 1 | Status: COMPLETED